SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 167.30 |
| Enterprise Value ($M) | 316.04 |
| Book Value ($M) | -40.01 |
| Book Value / Share | -0.26 |
| Price / Book | -4.18 |
| NCAV ($M) | -65.59 |
| NCAV / Share | -0.43 |
| Price / NCAV | -2.55 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.20 |
| Return on Assets (ROA) | -0.12 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.74 |
| Current Ratio | 2.28 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 195.19 |
| Assets | 220.78 |
| Liabilities | 260.78 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Adage Capital Management, L.P. | 5.84 | ||
| 13G | BlackRock, Inc. | 5.60 | 0.00 | |
| 13D/A | Rubric Capital Management LP | 17.70 | 0.00 | |
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G/A | Baker Bros. Advisors Lp | 4.99 | -3.07 | |
| 13G/A | Great Point Partners Llc | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 5.56 | 6.82 | |
| 13G/A | Franklin Resources Inc | 4.30 | -46.03 | |
| 13G/A | Jpmorgan Chase & Co | 0.00 | -98.75 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 253,316 | 902,709 | 28.06 | |
| 424,243 | 1,459,367 | 29.07 | |
| 459,072 | 1,551,389 | 29.59 | |
| 319,971 | 1,208,989 | 26.47 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| HEPA – Hepion Pharmaceuticals, Inc. | HOOK – HOOKIPA Pharma Inc. |
| HOTH – Hoth Therapeutics, Inc. | ICCC – ImmuCell Corporation |
| IKT – Inhibikase Therapeutics, Inc. |